Grifols (NASDAQ:GRFS) Sees Strong Trading Volume - Time to Buy?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) saw strong trading volume on Tuesday . 1,472,072 shares changed hands during mid-day trading, an increase of 21% from the previous session's volume of 1,212,583 shares.The stock last traded at $7.16 and had previously closed at $7.01.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley assumed coverage on Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Stock Up 0.4 %

The stock has a market cap of $4.96 billion, a price-to-earnings ratio of 6.16 and a beta of 0.41. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The firm's 50 day moving average is $7.47 and its two-hundred day moving average is $7.75.

Hedge Funds Weigh In On Grifols

A number of institutional investors have recently modified their holdings of GRFS. R Squared Ltd purchased a new stake in Grifols in the 4th quarter worth approximately $28,000. Versant Capital Management Inc purchased a new stake in shares of Grifols in the first quarter valued at $28,000. GAMMA Investing LLC increased its stake in Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,527 shares during the last quarter. Blue Trust Inc. lifted its position in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after buying an additional 6,335 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.